CA2683629C - Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods - Google Patents

Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods Download PDF

Info

Publication number
CA2683629C
CA2683629C CA2683629A CA2683629A CA2683629C CA 2683629 C CA2683629 C CA 2683629C CA 2683629 A CA2683629 A CA 2683629A CA 2683629 A CA2683629 A CA 2683629A CA 2683629 C CA2683629 C CA 2683629C
Authority
CA
Canada
Prior art keywords
mel
cell lines
microorganisms
deposited
access number
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2683629A
Other languages
English (en)
French (fr)
Other versions
CA2683629A1 (en
Inventor
Jose Mordoh
Maria Marcela Barrio
Erika Maria Von Euw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consejo Nacional de Investigaciones Científicas y Técnicas
Fundacion Sales
Inis Biotech LLC
Original Assignee
Consejo Nacional de Investigaciones Científicas y Técnicas
Fundacion Sales
Inis Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consejo Nacional de Investigaciones Científicas y Técnicas, Fundacion Sales, Inis Biotech LLC filed Critical Consejo Nacional de Investigaciones Científicas y Técnicas
Publication of CA2683629A1 publication Critical patent/CA2683629A1/en
Application granted granted Critical
Publication of CA2683629C publication Critical patent/CA2683629C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4273—Glycoprotein 100 [Gp100]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N13/00—Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/876—Skin, melanoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2683629A 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods Active CA2683629C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ARP20070101520 2007-04-11
ARP070101520A AR060424A1 (es) 2007-04-11 2007-04-11 Lineas celulares , composiciones para el tratamiento de melanomas que las comprenden procedimientos para preparar las composiciones y metodos de tratamiento
PCT/IB2008/051385 WO2008126039A2 (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods

Publications (2)

Publication Number Publication Date
CA2683629A1 CA2683629A1 (en) 2008-10-23
CA2683629C true CA2683629C (en) 2016-06-21

Family

ID=39590605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2683629A Active CA2683629C (en) 2007-04-11 2008-04-11 Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods

Country Status (17)

Country Link
US (1) US8501168B2 (cg-RX-API-DMAC7.html)
EP (1) EP2146742B1 (cg-RX-API-DMAC7.html)
JP (1) JP5762738B2 (cg-RX-API-DMAC7.html)
KR (1) KR101502518B1 (cg-RX-API-DMAC7.html)
CN (1) CN101861163B (cg-RX-API-DMAC7.html)
AR (1) AR060424A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008238909B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0809767B1 (cg-RX-API-DMAC7.html)
CA (1) CA2683629C (cg-RX-API-DMAC7.html)
CO (1) CO6260100A2 (cg-RX-API-DMAC7.html)
DK (1) DK2146742T3 (cg-RX-API-DMAC7.html)
ES (1) ES2390130T3 (cg-RX-API-DMAC7.html)
MX (1) MX2009010927A (cg-RX-API-DMAC7.html)
NZ (1) NZ580533A (cg-RX-API-DMAC7.html)
RU (1) RU2484134C2 (cg-RX-API-DMAC7.html)
WO (1) WO2008126039A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200907240B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6077735B2 (ja) * 2011-06-08 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
SG11201401631VA (en) 2011-10-20 2014-05-29 California Stem Cell Inc Antigen presenting cancer vaccine with gamma interferon
JP6077757B2 (ja) * 2012-04-17 2017-02-08 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
JP5921386B2 (ja) * 2012-08-27 2016-05-24 日本電子株式会社 電子顕微鏡観察用染色剤および電子顕微鏡観察用試料の染色方法
CN103146641B (zh) * 2013-02-06 2015-03-25 云南中科灵长类生物医学重点实验室 多能干细胞的传代方法及其用途
CN104990781B (zh) * 2015-06-29 2018-02-16 中国医学科学院皮肤病研究所 黑素细胞免疫组化苏木素—甲苯胺蓝双重复染法
AU2020395765A1 (en) 2019-12-03 2022-06-16 Neuvogen, Inc. Tumor cell vaccines
RU2755233C1 (ru) * 2021-01-11 2021-09-14 Сергей Анатольевич Яргунин Способ лечения меланомы кожи IIb-IIc стадий
CN115074328B (zh) * 2022-06-21 2025-02-07 中国人民解放军空军军医大学 一种用于治疗黑素瘤的细胞株及其多效价全细胞疫苗与使用方法
WO2025224605A1 (en) 2024-04-23 2025-10-30 Consejo Nacional De Investigaciones Científicas Y Técnicas (Conicet) Sequential administration of anti-melanoma vaccine and anti-pd-1 monoclonal antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5882654A (en) * 1989-11-03 1999-03-16 Morton; Donald L. Polyvalent melanoma vaccine
KR20000022445A (ko) * 1996-07-10 2000-04-25 크리스토퍼 엘. 와이트, 스코트 지. 홀퀴스트, 스티븐 엘. 말라스카 수상돌기 세포의 활성화 방법
AU3889997A (en) * 1996-08-16 1998-03-06 Johns Hopkins University School Of Medicine, The Melanoma cell lines expressing shared immunodominant melanoma antigens nd methods of using same
WO1999042564A2 (en) * 1998-02-20 1999-08-26 The Rockefeller University Apoptotic cell-mediated antigen presentation to dendritic cells
US7988963B1 (en) * 1999-10-15 2011-08-02 Baylor Research Institute Use of allogeneic cell lines to load antigen presenting cells to elicit or eliminate immune responses
WO2001028583A2 (en) * 1999-10-18 2001-04-26 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
US7015205B1 (en) * 1999-10-18 2006-03-21 St. Vincent's Hospital And Medical Center Of New York Melanoma vaccine and methods of making and using same
WO2001048154A1 (en) * 1999-12-28 2001-07-05 Toyoshima, Kumao Maturation-promoting agent for immature dendritic cells
EP1326961B1 (en) * 2000-09-15 2007-08-22 Ortho-McNeil Pharmaceutical, Inc. Compositions and methods for inducing specific cytolytic t cell responses
US20030072737A1 (en) * 2000-12-29 2003-04-17 Michael Brines Tissue protective cytokines for the protection, restoration, and enhancement of responsive cells, tissues and organs
IL140796A0 (en) * 2001-01-08 2002-02-10 Hadasit Med Res Service An autologous anti-cancer vaccine
CA2440229A1 (en) * 2001-03-09 2002-09-19 Baylor Research Institute Method of treating malignancies through induction of blood immune responses
US7354909B2 (en) * 2001-08-14 2008-04-08 The United States Of America As Represented By Secretary Of The Department Of Health And Human Services Method for rapid generation of mature dendritic cells
EP1451305A4 (en) * 2001-11-07 2005-10-05 Mannkind Corp EPITOPE SYNCHRONIZATION IN CELLS THAT HAVE ANTIGENS
CN102600461B (zh) * 2002-12-06 2017-07-14 西北生物治疗药物公司 给予体外部分成熟的树突细胞治疗肿瘤
EP1623011B1 (en) * 2003-05-09 2013-01-02 Janssen Biotech, Inc. Il-23p40 specific immunoglobulin derived proteins, compositions, methods and uses
JP5021309B2 (ja) * 2003-10-16 2012-09-05 ステファン ジョン ラルフ 免疫調節性組成物およびその使用方法
RU2262941C2 (ru) 2004-01-05 2005-10-27 Государственное учреждение Научно-исследовательский институт клинической иммунологии СО РАМН Способ иммунотерапии злокачественных опухолей головного мозга
EP1740946B1 (en) * 2004-04-20 2013-11-06 Genmab A/S Human monoclonal antibodies against cd20
CA2565874C (en) * 2004-05-10 2017-10-03 Macrogenics, Inc. Humanized fc.gamma.riib-specific antibodies and methods of use thereof
RU2283129C1 (ru) 2004-12-24 2006-09-10 Сергей Викторович Луценко Белковопептидный противоопухолевый композит, клеточный препарат, активированный этим композитом, и способ профилактики или лечения опухолей

Also Published As

Publication number Publication date
KR101502518B1 (ko) 2015-03-13
US20100183683A1 (en) 2010-07-22
JP5762738B2 (ja) 2015-08-12
MX2009010927A (es) 2010-02-11
WO2008126039A3 (en) 2008-12-11
CA2683629A1 (en) 2008-10-23
EP2146742B1 (en) 2012-07-11
JP2010523141A (ja) 2010-07-15
RU2484134C2 (ru) 2013-06-10
ES2390130T3 (es) 2012-11-06
BRPI0809767A2 (pt) 2014-09-23
AR060424A1 (es) 2008-06-18
US8501168B2 (en) 2013-08-06
ZA200907240B (en) 2010-07-28
BRPI0809767B1 (pt) 2022-04-12
WO2008126039A2 (en) 2008-10-23
CN101861163A (zh) 2010-10-13
RU2009141593A (ru) 2011-05-20
NZ580533A (en) 2012-08-31
CO6260100A2 (es) 2011-03-22
CN101861163B (zh) 2013-06-12
AU2008238909A1 (en) 2008-10-23
DK2146742T3 (da) 2012-10-22
KR20090129501A (ko) 2009-12-16
EP2146742A2 (en) 2010-01-27
AU2008238909B2 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
AU2008238909B2 (en) Cell lines, compositions comprising them for the treatment of melanomas, procedures to prepare the compositions, and treatment methods
Palucka et al. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity
AU723607B2 (en) Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
US7015205B1 (en) Melanoma vaccine and methods of making and using same
JP5986196B2 (ja) 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法
JP2016041725A (ja) ＧＭ−ＣＳＦ及びインターフェロンαを用いて生成され、且つ熱処理され死滅したがん細胞を取り込んだ樹状細胞
CN107541498A (zh) 一种tcr基因修饰的cd8+t记忆性干细胞的制备方法及其用途
US20100303868A1 (en) Ex vivo, fast and efficient process to obtain activated antigen-presenting cells that are useful for therapies against cancer and immune system-related diseases
JP2017025066A (ja) 高静水圧によって死滅させた腫瘍細胞および樹状細胞を用いた活性細胞癌免疫療法のための手段および方法
JP6602377B2 (ja) 樹状細胞の製造方法、これにより製造された樹状細胞及びその用途
WO2002053176A2 (en) An autologous anti-cancer vaccine
WO2001028583A2 (en) Melanoma vaccine and methods of making and using same
US20170100438A1 (en) Treatment of glioma by anti-angiogenic active immunization for direct tumor inhibition and augmentation of chemotherapy, immunotherapy and radiotherapy efficacy
Wang et al. Generating renal cancer-reactive T cells using dendritic cells (DCs) to present autologous tumor
CA2265925A1 (en) Semi-allogeneic cell hybrids as preventive and therapeutic vaccines for cancer and aids
EP1227838B1 (en) Melanoma vaccine and methods of making and using same
HK1049114B (en) Melanoma vaccine and methods of making and using same
AU2007202210A1 (en) Rapid one-step method for generation of antigen loaded dendritic cell vaccine from precursors

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20130405

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250429

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250429

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260223

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 18TH ANNIV.) - STANDARD

Year of fee payment: 18

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260324

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260324